```
=> d his

     (FILE 'HCAPLUS' ENTERED AT 08:56:42 ON 17 JUL 2003)
               DEL HIS Y

     FILE 'REGISTRY' ENTERED AT 08:57:19 ON 17 JUL 2003
               ACT DESAI/A
               ---------
L1             STR
L2         34103 SEA FILE=REGISTRY SSS FUL L1
               ---------
               ACT DESAI2/A
               ---------
L3             STR
L4            28 SEA FILE=REGISTRY SSS FUL L3
               ---------

     FILE 'HCAPLUS' ENTERED AT 08:57:59 ON 17 JUL 2003
L5         16634 S L2
L6             7 S L4
L7       1272711 S POLYMER?
L8           847 S L5 AND L7
L9         92482 S CONJUGAT?
L10          149 S L8 AND L9
L11        86623 S DRUG DELIVER?
L12           48 S L10 AND L11
L13            8 S L12 AND PRODRUG
L14         1457 S  PAYLOAD? OR PAYLOAD?/AB
L15            1 S L12 AND L14
L16        30361 S (CONTROL? OR SLOW OR TIME? OR SUSTAIN?) (L) (RELEAS?)
L17            6 S L12 AND L16
L18           12 S L17 OR L15 OR L13
               SELECT RN L18 HIT 1-12
```

Clock

L6 - #4 of 7 "?"

L18 #7 of 12 102(b)

#11 of 12 102(a)

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 09:02:40 ON 17 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   16 JUL 2003  HIGHEST RN 549206-78-2
DICTIONARY FILE UPDATES:  16 JUL 2003  HIGHEST RN 549206-78-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d que stat l2
```

page 46 - 2 smaller structures

```
L1                STR
```




```
VAR G1=4/18
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  30

STEREO ATTRIBUTES: NONE
L2        34103 SEA FILE=REGISTRY SSS FUL L1
```

100.0% PROCESSED 350420 ITERATIONS 34103 ANSWERS
SEARCH TIME: 00.00.08

→ page 45 and longer structure on page 46

=> d que stat l4
L3 STR



48 52

Page 1-A



Page 2-A
VAR G1=36/7
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 56

STEREO ATTRIBUTES: NONE
L4 28 SEA FILE=REGISTRY SSS FUL L3

```
100.0% PROCESSED 160407 ITERATIONS                          28 ANSWERS
SEARCH TIME: 00.00.07


=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 09:02:50 ON 17 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 17 Jul 2003  VOL 139 ISS 3
FILE LAST UPDATED: 16 Jul 2003  (20030716/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d que nos l6
L3              STR
L4           28 SEA FILE=REGISTRY SSS FUL L3
L6            7 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L4


=> d que nos l18
L1              STR
L2        34103 SEA FILE=REGISTRY SSS FUL L1
L5        16634 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2
L7      1272711 SEA FILE=HCAPLUS ABB=ON  PLU=ON  POLYMER?/OBI
L8          847 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L5 AND L7
L9        92482 SEA FILE=HCAPLUS ABB=ON  PLU=ON  CONJUGAT?/OBI
L10         149 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L8 AND L9
L11       86623 SEA FILE=HCAPLUS ABB=ON  PLU=ON  DRUG DELIVER?/OBI
L12          48 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L10 AND L11
L13           8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L12 AND PRODRUG/OBI
L14        1457 SEA FILE=HCAPLUS ABB=ON  PLU=ON  PAYLOAD?/OBI OR PAYLOAD?/AB
L15           1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L12 AND L14
L16       30361 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (CONTROL?/OBI OR SLOW/OBI OR
                TIME?/OBI OR SUSTAIN?/OBI) (L) (RELEAS?/OBI)
L17           6 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L12 AND L16
L18          12 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L17 OR L15 OR L13


=> d .ca hitstr l6 1-7;d .ca hitstr l18 1-12

L6   ANSWER 1 OF 7  HCAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:        2003:376579  HCAPLUS
```

DOCUMENT NUMBER: 138:390913
TITLE: Polymeric thiol-linked prodrugs
INVENTOR(S): Choe, Yun Hwang; Greenwald, Richard B.
PATENT ASSIGNEE(S): Enzon, Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039479	A2	20030515	WO 2002-US35868	20021108

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-344914P P 20011109
US 2002-367320P P 20020325
OTHER SOURCE(S): MARPAT 138:390913

AB Thiol-linked polymeric prodrugs and methods of making and using the same are disclosed. The use of a sulfhydryl bond as the basic link for linking the polymer to the drug allows a prodrug to be formed which takes advantage of plasma enzymes in vivo. A preferred conjugate is a PEG-6-MP conjugate (prepn. given), showing roughly 25-35% redn. in tumor growth as compared to 6-MP.

IC ICM A61K
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 35
IT 452369-71-0P 524961-31-7P 524961-33-9P 524961-36-2P 524961-39-5P **524961-41-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of polymeric thiol-linked prodrugs)
IT 608-09-3P 150109-41-4P 150109-43-6P 152293-46-4P 153354-68-8P 167082-77-1P 188636-64-8P 396134-22-8P 452369-72-1P **474083-07-3P 474083-09-5P** 524961-30-6P 524961-32-8P 524961-35-1P 524961-37-3P 524961-38-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of polymeric thiol-linked prodrugs)
IT **524961-40-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of polymeric thiol-linked prodrugs)
IT **524961-41-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of polymeric thiol-linked prodrugs)
RN 524961-41-9 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, monoether with hydroxyacetyl-L-aspartoylbis[L-aspartoylbis[L-aspartoylbis[.beta.-alanine]]] octakis[(1H-purin-6-ylthio)methyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 3-A





PAGE 3-B



IT **474083-07-3P 474083-09-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of polymeric thiol-linked prodrugs)
RN 474083-07-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, monoether with N-(hydroxyacetyl)-L-aspartoylbis[L-aspartic acid] tetramethyl ester (9CI) (CA INDEX NAME)



RN 474083-09-5 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, monoether with N-(hydroxyacetyl)-L-aspartoylbis[L-aspartic acid] (9CI) (CA INDEX NAME)



IT **524961-40-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of polymeric thiol-linked prodrugs)
RN 524961-40-8 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, monoether with hydroxyacetyl-L-aspartoylbis[L-aspartoylbis[.beta.-alanine]] tetrakis[(1H-purin-6-ylthio)methyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 3-A



L6 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:130614 HCAPLUS
DOCUMENT NUMBER: 137:341957
TITLE: Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors
AUTHOR(S): Choe, Yun H.; Conover, Charles D.; Wu, Dechun; Royzen, Maksim; Gervacio, Yoany; Borowski, Virna; Mehlig, Mary; Greenwald, Richard B.
CORPORATE SOURCE: Enzon, Inc., Piscataway, NJ, 08854-3969, USA
SOURCE: Journal of Controlled Release (2002), 79(1-3), 55-70
CODEN: JCREEC; ISSN: 0168-3659

PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis of branched PEG (40,000) acids has been achieved using aspartic acid (Asp) and AspAsp dendrons. Complete conjugation of these dendritic acids with cytosine arabinoside (ara-C) was achieved by the use of spacers that allowed a greater sepn. of the branches to accommodate several large ara-C mols. in proximity to each other. The tetrameric and octameric PEG-ara-C amide prodrugs were much more effective in the treatment of solid and ascites tumors compared to the native drug. The greater loading of the PEG backbone appears to have achieved a min. threshold concn. for the therapeutic delivery of ara-C.

CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1, 33, 35

IT 452369-80-1P 452943-24-7P 452952-59-9P 474083-30-2P
474083-34-6P 474083-36-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and efficacy in ascites and solid tumors of multi-loaded N4-acyl polyethylene glycol prodrugs of ara-C)

IT 108466-89-3P 167082-77-1P 187978-51-4P 229958-24-1P 229958-26-3P
229958-32-1P 379711-88-3P 379711-89-4P 396133-75-8P 396133-77-0P
396134-31-9P 452347-80-7P 452347-83-0P 452369-70-9P 452369-73-2P
452369-74-3P 452369-75-4P 452369-76-5P 452369-77-6P 452369-79-8P
474083-03-9P 474083-05-1P **474083-07-3P 474083-09-5P**
474083-17-5P 474083-19-7P 474083-21-1P 474083-25-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and efficacy in ascites and solid tumors of multi-loaded N4-acyl polyethylene glycol prodrugs of ara-C)

IT **474083-34-6P 474083-36-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and efficacy in ascites and solid tumors of multi-loaded N4-acyl polyethylene glycol prodrugs of ara-C)

RN 474083-34-6 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, 1-ether with hydroxyacetyl-L-aspartoylbis[N1,N4-bis[2-[2-[2-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-2-oxoethoxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



PAGE 4-B



RN 474083-36-8 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, 1-ether with hydroxyacetyl-L-aspartoylbis[N1,N4-bis[2-[2-[2-[[(1S)-1-[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]carbonyl]-3-methylbutyl]amino]-2-oxoethoxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



PAGE 4-B



IT **474083-07-3P 474083-09-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and efficacy in ascites and solid tumors of multi-loaded N4-acyl polyethylene glycol prodrugs of ara-C)

RN 474083-07-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, monoether with N-(hydroxyacetyl)-L-aspartoylbis[L-aspartic acid] tetramethyl ester (9CI) (CA INDEX NAME)



RN 474083-09-5 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, monoether with N-(hydroxyacetyl)-L-aspartoylbis[L-aspartic acid] (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:107826 HCAPLUS
DOCUMENT NUMBER: 136:172758
TITLE: Terminally-branched polymeric linkers containing extension moieties for prodrug conjugates
INVENTOR(S): Greenwald, Richard B.; Choe, Yun H.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 32 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002015691	A1	20020207	US 2001-823296	20010329

PRIORITY APPLN. INFO.: US 2000-193931P P 20000331

AB The present invention relates to polymer-based (e.g., PEG) conjugates having increased therapeutic payloads. In particular, the invention relates to the use of extension moieties which increase the efficiency of the loading of drugs onto the polymeric carriers. A variety of prodrugs were prepd. from ara-C and PEG derivs. by using spacer groups. The prodrug demonstrated better antitumor activity than ara-C alone. The prodrug produced complete tumor regression.

IC ICM A61K031-785
ICS C08G073-00
NCL 424078360

mine claims priority to 60/193,931 3/31/00 same provisional NOT

This is the application I am reviewing

This is my application # currently. Not an issued patent. "?"

8/15/03
This is my application!!

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 37

IT 396133-96-3P 396133-97-4P 396133-98-5P 396133-99-6P 396134-00-2P
396134-01-3P 396134-02-4P 396134-06-8P 396134-07-9P 396134-08-0P
396134-09-1P 396134-10-4P 396134-11-5P 396134-12-6P
396134-15-9P 396134-16-0P 396134-17-1P
396134-18-2P 396134-19-3P 396134-20-6P
396134-21-7P 397244-13-2P 397244-15-4P 397244-37-0P
397244-38-1P 397244-39-2P 397244-40-5P 397245-64-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(terminally-branched polymeric linkers contg. extension moieties for prodrug conjugates)

IT 80681-05-6P 96989-50-3P 108466-89-3P 139115-91-6P 167082-77-1P
188636-64-8P 259802-47-6P 261364-63-0P 341551-69-7P 379711-88-3P
379711-89-4P 396133-72-5P 396133-74-7P 396133-75-8P 396133-77-0P
396133-78-1P 396133-79-2P 396133-81-6P 396133-82-7P 396133-83-8P
396133-85-0P 396133-86-1P 396133-88-3P 396133-89-4P 396133-90-7P
396133-92-9P 396133-93-0P 396133-95-2P 396134-04-6P
396134-13-7P 396134-14-8P 396134-22-8P
396134-24-0P 396134-25-1P 396134-28-4P 396134-30-8P
396134-31-9P 397245-65-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(terminally-branched polymeric linkers contg. extension moieties for prodrug conjugates)

IT **367928-61-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(terminally-branched polymeric linkers contg. extension moieties for prodrug conjugates)

IT **396134-15-9P 396134-16-0P 396134-17-1P**
396134-18-2P 396134-19-3P 396134-20-6P
396134-21-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(terminally-branched polymeric linkers contg. extension moieties for prodrug conjugates)

RN 396134-15-9 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1-ether with N-(hydroxyacetyl)-L-aspartoylbis[N1,N4-bis[2-[2-[[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]carbonyl]oxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



RN 396134-16-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1-ether with N-(hydroxyacetyl)-L-aspartoylbis[N1,N4-bis[2-[2-[2-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-2-oxoethoxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



PAGE 4-B



RN 396134-17-1 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1-ether with N-(hydroxyacetyl)-L-aspartoylbis[N1,N4-bis[2-[2-[2-[[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]carbonyl]amino]ethoxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



PAGE 4-B



RN 396134-18-2 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1-ether with N-(hydroxyacetyl)-L-aspartoylbis[N1,N4-bis[2-[2-[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]thioxomethoxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



RN 396134-19-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1-ether with N-(hydroxyacetyl)-L-aspartoylbis[N1,N4-bis[2-[2-[2-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-2-thioxoethoxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



PAGE 4-B



RN 396134-20-6 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1-ether with N-(hydroxyacetyl)-L-aspartoylbis[N1,N4-bis[2-[2-[2-[[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]thioxomethyl]amino]ethoxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



PAGE 4-B



RN 396134-21-7 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, ether with hydroxyacetyl-L-aspartoylbis[N1,N4-bis[2-[2-[[[[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]oxy]carbonyl]oxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 3-A



IT **396134-13-7P 396134-14-8P 396134-24-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(terminally-branched polymeric linkers contg. extension moieties for prodrug conjugates)
RN 396134-13-7 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, ether with N-(hydroxyacetyl)-L-aspartoylbis[L-aspartic acid] tetramethyl ester (9CI) (CA INDEX NAME)



RN 396134-14-8 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, ether with N-(hydroxyacetyl)-L-aspartoylbis[L-aspartic acid] (9CI) (CA INDEX NAME)



RN 396134-24-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, ether with N-(hydroxyacetyl)-L-aspartoylbis[L-aspartoylbis[L-aspartic acid]] (9CI) (CA INDEX NAME)

PAGE 1-A



— CO_2H

— CH(— CO_2H) — CH_2 — CO_2H

IT **367928-61-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(terminally-branched polymeric linkers contg. extension moieties for prodrug conjugates)
RN 367928-61-8 HCAPLUS
CN L-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-L-aspartoylbis[L-aspartoylbis-, octamethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:527237 HCAPLUS
DOCUMENT NUMBER: 129:172519
TITLE: Compounds comprising a linear, branched or dendritic polymer backbone for use in medical imaging
INVENTOR(S): Wolfe, Henry; Kellar, Kenneth
PATENT ASSIGNEE(S): Nycomed Imaging A/S, Norway; Golding, Louise
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9832469	A2	19980730	WO 1998-GB270	19980129
WO 9832469	A3	19981105		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9858717	A1	19980818	AU 1998-58717	19980129
EP 1011736	A2	20000628	EP 1998-902085	19980129
R: DE, DK, ES, FR, GB, IT, SE, IE, FI				
JP 2001509796	T2	20010724	JP 1998-531761	19980129
MX 9906836	A	20000131	MX 1999-6836	19990722
NO 9903662	A	19990928	NO 1999-3662	19990728
US 2002076378	A1	20020620	US 2002-57943	20020129

PRIORITY APPLN. INFO.:		
GB 1997-1813	A	19970129
US 1997-57074P	P	19970827
WO 1998-GB270	W	19980129
US 1999-362711	A	19990729

AB The invention provides compds. comprising a linear, branched or dendrimeric polymer backbone with linked thereto at least one reporter moiety, said polymer backbone comprising a plurality of amine-contg. acids. Such compds. may be linked to one or more targeting agents and are useful as therapeutic and diagnostic agents, in particular in medical imaging techniques.

IC ICM A61K049-04
ICS A61K049-00

CC 8-9 (Radiation Biochemistry)
Section cross-reference(s): 34, 63

IT 211176-27-1P **211176-28-2P 211176-29-3P** 211176-30-6P
211365-72-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(compds. comprising a linear, branched or dendritic polymer backbone for use in medical imaging)

IT **211176-28-2P 211176-29-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(compds. comprising a linear, branched or dendritic polymer backbone for use in medical imaging)

RN 211176-28-2 HCAPLUS

CN L-Aspartic acid, N-[(phenylmethoxy)carbonyl]-L-aspartoylbis[L-aspartoylbis-, octakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

OBu-t

OBu-t

RN 211176-29-3 HCAPLUS
CN L-Aspartic acid, N-[(phenylmethoxy)carbonyl]-L-aspartoylbis[L-aspartoylbis[L-aspartoylbis-, hexadecakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



L6 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:142849 HCAPLUS
DOCUMENT NUMBER: 126:251387
TITLE: Synthesis of totally chiral, multiple armed, poly Glu and poly Asp scaffoldings on bifunctional adamantane core
AUTHOR(S): Ranganathan, Darshan; Kurur, Sunita
CORPORATE SOURCE: Biomolecular Research Unit, Regional Research Laboratory (CSIR), Trivandrum, 695019, India
SOURCE: Tetrahedron Letters (1997), 38(7), 1265-1268
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Three successive generations of peptidic scaffoldings consisting of 2, 6, and 14 chiral (all L) centers and 4, 8, and 16 carbomethoxy groups, resp., at the periphery with adamantane nucleus as the central core have been constructed by linking the two halves of corresponding Asp/Glu dendrons by a 1,3-adamantanedicarboxylic acid unit. Energy minimization and 1H NMR studies have shown these scaffoldings to adopt increasingly globular and compact architecture with each succeeding generation.

CC 34-3 (Amino Acids, Peptides, and Proteins)
IT 6384-18-5, Dimethyl aspartate 6525-53-7, Dimethyl glutamate 29713-15-3, 1,3-Adamantanedicarbonyl chloride 188636-64-8 188636-65-9 **188636-66-0** 188636-67-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of totally chiral, multiple armed, polyglutamate and polyaspartate scaffoldings on bifunctional adamantane core)

IT **188636-58-0P** **188636-59-1P** **188636-60-4P** **188636-61-5P**
188636-62-6P **188636-63-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of totally chiral, multiple armed, polyglutamate and polyaspartate scaffoldings on bifunctional adamantane core)

IT **188636-66-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of totally chiral, multiple armed, polyglutamate and polyaspartate scaffoldings on bifunctional adamantane core)

RN 188636-66-0 HCAPLUS
CN L-Aspartic acid, L-aspartoylbis[L-aspartoylbis-, octamethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **188636-62-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of totally chiral, multiple armed, polyglutamate and polyaspartate scaffoldings on bifunctional adamantane core)

RN 188636-62-6 HCAPLUS
CN L-Aspartic acid, 1,1''''-(tricyclo[3.3.1.13,7]decane-1,3-diyldicarbonyl)bis[L-aspartoylbis[L-aspartoylbis-, hexadecamethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



L6 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:516378 HCAPLUS
DOCUMENT NUMBER: 125:248545
TITLE: Polymerizable dendrimers. Part 2. Mono-methacryl-modified dendrimers containing up to 16 ester functions via stepwise condensations of L-aspartic acids
AUTHOR(S): Niggemann, M.; Ritter, H.
CORPORATE SOURCE: Fachbereich 9, Macromolecular Chem., Bergische Univ. Gesamthochschule, Wuppertal, D-42097, Germany
SOURCE: Acta Polymerica (1996), 47(8), 351-356
CODEN: ACPODY; ISSN: 0323-7648
PUBLISHER: VCH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A convergent synthesis of polymerizable dendrimers consisting of 1 methacrylic function combined with an alkylene spacer and several condensed L-aspartic acid components is described. The highly functionalized monomers were prepd. from 11-(N-methacryloylamino)undecanoic acid via condensation with free amino groups of L-aspartic acid di-Me ester, .alpha.,.beta.-bis-(L-dimethoxyaspartyl)-L-aspartic acid hydrobromide, and .alpha.,.beta.-bis-(L-aspartyl-.alpha.,.beta.-bis-(L-dimethoxyaspartyl))-L-aspartic acid hydrobromide. The no. of ester groups increased from 2 to 4 and 8, up to 16, depending on the dendritic generation of the condensed amino acids. The monomers were homopolymd. and copolymd. with styrene through a free radical mechanism.

CC 35-2 (Chemistry of Synthetic High Polymers)
Section cross-reference(s): 34

IT **182197-70-2P 182197-71-3P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(intermediate; prepn. and polymn. of stepwise condensed dendritic monomers and macromonomers from L-aspartic acid)

IT **182197-74-6P 182197-75-7P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(monomer; prepn. and polymn. of stepwise condensed dendritic monomers and macromonomers from L-aspartic acid)

IT **182269-38-1P 182269-39-2P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and polymn. of stepwise condensed dendritic monomers and macromonomers from L-aspartic acid)

IT **182197-70-2P 182197-71-3P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(intermediate; prepn. and polymn. of stepwise condensed dendritic monomers and macromonomers from L-aspartic acid)

RN 182197-70-2 HCAPLUS
CN L-Aspartic acid, N-[(phenylmethoxy)carbonyl]-L-aspartoylbis[L-aspartoylbis-, octamethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

OMe

OMe

RN 182197-71-3 HCAPLUS
CN L-Aspartic acid, L-aspartoylbis[L-aspartoylbis-, octamethyl ester, monohydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

● HBr

IT **182197-74-6P 182197-75-7P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(monomer; prepn. and polymn. of stepwise condensed dendritic monomers and macromonomers from L-aspartic acid)

RN 182197-74-6 HCAPLUS

CN L-Aspartic acid, N-[11-[(2-methyl-1-oxo-2-propenyl)amino]-1-oxoundecyl]-L-aspartoylbis-, tetramethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182197-75-7 HCAPLUS

CN L-Aspartic acid, N-[11-[(2-methyl-1-oxo-2-propenyl)amino]-1-oxoundecyl]-L-aspartoylbis[L-aspartoylbis-, octamethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **182269-38-1P 182269-39-2P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and polymn. of stepwise condensed dendritic monomers and macromonomers from L-aspartic acid)

RN 182269-38-1 HCAPLUS

CN L-Aspartic acid, N-[11-[(2-methyl-1-oxo-2-propenyl)amino]-1-oxoundecyl]-L-aspartoylbis-, tetramethyl ester, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 182197-74-6
CMF C31 H50 N4 O12

Absolute stereochemistry.



RN 182269-39-2 HCAPLUS

CN L-Aspartic acid, N-[11-[(2-methyl-1-oxo-2-propenyl)amino]-1-oxoundecyl]-L-aspartoylbis[L-aspartoylbis-, octamethyl ester, polymer with ethenylbenzene (9CI) (CA INDEX NAME)

CM 1

CRN 182197-75-7
CMF C51 H78 N8 O24

Absolute stereochemistry.



CM 2

CRN 100-42-5
CMF C8 H8

H_2C═CH—Ph

L6 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:6155 HCAPLUS
DOCUMENT NUMBER: 114:6155
TITLE: Preparation of metalloporphyrins useful in diagnosis and treatment of cancer
INVENTOR(S): Sakata, Isao; Nakajima, Susumu; Koshimizu, Koichi; Takada, Hiroyuki; Inui, Hiroshi
PATENT ASSIGNEE(S): Toyo Hakka Kogyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 48 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 350948	A2	19900117	EP 1989-112955	19890714
EP 350948	A3	19910605		
EP 350948	B1	19980318		
R: CH, DE, FR, GB, IT, LI				
JP 02138280	A2	19900528	JP 1989-146615	19890612

JP 2520735 B2 19960731
PRIORITY APPLN. INFO.: JP 1988-173835 19880714
JP 1989-146615 19890612
OTHER SOURCE(S): MARPAT 114:6155
GI



I

AB Title compds. I (R1, R2 = H2C:CH, Me(RO)CH, Me(RO-alkylene-O)CH; R3, R4 = HO or a residue obtained by removing a H from a polyfunctional compd.; R = H, alkenyl, alkyl, perfluoroalkyl, cyclic compd., or a residue obtained by removing a H from a polyfunctional compd.; M = metal) are prepd. To I [R1, R2 = 1-(decyloxy)ethyl; R3, R4 = OH; M = Mn] dicyclohexylamine salt were added and dissolved CHCl3 and MeCN, and to the resultant soln. were added H-Asp(OMe)-OH.HCl and 10% DCC/CHCl3 with stirring to give I [R1,R2 = 1-(decyloxy)ethyl; R3, R4 = aspartyl; M = Mn] (II). Tumor bearing hamsters given II 10 mg/mL dild. by phosphate buffer at 25 mg/kg, resulted in tumor growth inhibitory effect compared to controls, indicating a carcinostatic activity.

IC ICM C07D487-22
ICS A61K031-40; A61K049-00
ICI C07D487-22, C07D257-00, C07D209-00
CC 26-7 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1, 34
IT 553-12-8DP, manganese complexes 31444-62-9DP, gallium complexes 129639-22-1DP, gallium complexes 129639-23-2DP, gallium complexes 129639-24-3DP, gallium complexes 129639-25-4DP, gallium complexes 129639-26-5DP, gallium complexes 129639-27-6DP, gallium complexes 129639-28-7DP, gallium complexes 129639-29-8DP, gallium complexes 129639-30-1DP, gallium complexes 129639-31-2DP, gallium complexes 129669-45-0DP, gallium complexes 129669-46-1DP, manganese complexes 129669-47-2DP, gallium complexes 129669-48-3DP, gallium complexes 129669-51-8DP, gallium complexes 129669-52-9DP, gallium complexes 129735-26-8DP, manganese complexes 129868-94-6P 129901-27-5DP, gallium complexes 129901-27-5DP, manganese complexes 129901-28-6DP, gallium complexes 129901-28-6DP, manganese complexes 129901-29-7DP, gallium complexes 129901-29-7DP, manganese complexes 129901-30-0DP, gallium complexes 129901-30-0DP, manganese complexes 129901-31-1DP, gallium complexes 129901-32-2DP, gallium complexes 129901-33-3DP, gallium complexes 129901-34-4DP, gallium complexes 129901-35-5DP, gallium complexes 129901-36-6DP, gallium complexes 129901-37-7DP, gallium complexes 129901-38-8DP, Mn complexes 129901-38-8DP, cobalt complexes 129901-38-8DP, gallium complexes 129901-38-8P 129901-39-9DP, Mn complexes 129901-39-9DP, cobalt complexes 129901-39-9DP, copper complexes 129901-39-9DP, gallium complexes 129901-39-9DP, iron complexes 129901-39-9P 129901-40-2DP, gallium complexes

129901-41-3DP, gallium complexes 129901-42-4DP, gallium complexes
129901-43-5DP, gallium complexes 129901-44-6DP, gallium complexes
129901-45-7DP, gallium complexes 129901-46-8DP, gallium complexes
129901-47-9DP, gallium complexes 129901-48-0DP, Mn complexes
129901-48-0DP, gallium complexes 129901-49-1DP, gallium complexes
129901-51-5DP, gallium complexes 129901-52-6DP, gallium complexes
129901-53-7DP, gallium complexes 129901-54-8DP, gallium complexes
129901-55-9DP, gallium complexes 129901-56-0DP, gallium complexes
129901-57-1DP, gallium complexes 129901-58-2DP, Mn complexes
129901-58-2DP, gallium complexes 129901-59-3DP, Mn complexes
129901-59-3DP, cobalt complexes 129901-59-3DP, gallium complexes
129901-60-6DP, gallium complexes 129901-60-6DP, manganese complexes
129901-60-6P 129901-61-7DP, gallium complexes 129901-61-7DP, manganese complexes 129901-62-8DP, gallium complexes 129901-63-9DP, cobalt complexes 129901-63-9DP, copper complexes 129901-63-9DP, gallium complexes 129901-63-9DP, iron complexes 129901-63-9DP, manganese complexes 129901-64-0DP, gallium complexes 129901-66-2DP, gallium complexes 129901-66-2DP, manganese complexes 129901-67-3DP, gallium complexes 129901-67-3DP, manganese complexes 129901-68-4DP, Mn complexes 129901-68-4P 129901-69-5DP, Mn complexes 129901-69-5P 129901-70-8DP, Mn complexes 129901-70-8P 129901-72-0DP, gallium complexes 129901-72-0DP, manganese complexes 129901-73-1DP, manganese complexes 129901-75-3DP, Mn complexes 129901-75-3DP, gallium complexes 129901-75-3DP, iron complexes 129901-76-4DP, Mn complexes
129901-77-5DP, Mn complexes 129901-78-6DP, Mn complexes 129901-79-7DP, Mn complexes 129901-80-0DP, Mn complexes 129901-81-1DP, Mn complexes
129901-82-2DP, Mn complexes 129901-83-3DP, Mn complexes 129901-84-4DP, Mn complexes 129901-85-5DP, Mn complexes 129901-87-7DP, manganese complexes 129901-87-7P 129901-88-8DP, manganese complexes
129901-89-9DP, manganese complexes 129901-89-9P 129901-90-2DP, manganese complexes 129901-90-2P 129901-91-3DP, manganese complexes
129901-91-3P 129901-92-4DP, gallium complexes 129901-92-4DP, manganese complexes 129901-92-4P **129901-93-5DP**, manganese complexes
129901-94-6DP, manganese complexes 129901-97-9DP, manganese complexes
129901-98-0DP, manganese complexes 129901-99-1DP, manganese complexes
129901-99-1P 129902-00-7DP, manganese complexes 129902-01-8DP, manganese complexes 129902-02-9DP, manganese complexes 129902-03-0DP, manganese complexes 129902-42-7DP, gallium complexes 129902-42-7DP, iron complexes 129926-28-9DP, gallium complexes 129926-29-0DP, gallium complexes 129926-30-3DP, gallium complexes 129926-30-3DP, manganese complexes 129926-31-4DP, iron complexes 129926-31-4DP, manganese complexes 129926-32-5DP, manganese complexes 129926-33-6DP, manganese complexes 129926-34-7DP, manganese complexes 129926-35-8DP, manganese complexes 129926-36-9DP, manganese complexes 129926-37-0DP, manganese complexes 129996-41-4DP, gallium complexes 130593-79-2DP, manganese complexes
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation)
(prepn. of, as antitumor agent)

IT **129901-93-5DP**, manganese complexes
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation)
(prepn. of, as antitumor agent)

RN 129901-93-5 HCAPLUS

CN L-Aspartic acid, 1,1''-[[3,7,12,17-tetramethyl-8,13-bis[1-(octadecyloxy)ethyl]-21H,23H-porphine-2,18-diyl]bis(1-oxo-3,1-propanediyl)]bis[L-aspartoylbis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



— Me

L18 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:376579 HCAPLUS
DOCUMENT NUMBER: 138:390913
TITLE: **Polymeric** thiol-linked **prodrugs**
INVENTOR(S): Choe, Yun Hwang; Greenwald, Richard B.
PATENT ASSIGNEE(S): Enzon, Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039479	A2	20030515	WO 2002-US35868	20021108

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-344914P P 20011109
US 2002-367320P P 20020325

OTHER SOURCE(S): MARPAT 138:390913

AB Thiol-linked polymeric prodrugs and methods of making and using the same are disclosed. The use of a sulfhydryl bond as the basic link for linking the polymer to the drug allows a prodrug to be formed which takes advantage of plasma enzymes in vivo. A preferred conjugate is a PEG-6-MP conjugate (prepn. given), showing roughly 25-35% redn. in tumor growth as compared to 6-MP.

IC ICM A61K

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 35

ST **polymer conjugate** thiol link **prodrug** prepn; mercaptopurine polyethylene glycol **conjugate** prepn antitumor

IT **Polymer** degradation kinetics
(hydrolytic; prepn. of **polymeric** thiol-linked **prodrugs**)

IT Antitumor agents
(prepn. of **polymeric** thiol-linked **prodrugs**)

IT **Drug delivery** systems
(**prodrugs**; prepn. of **polymeric** thiol-linked **prodrugs**)

IT 452369-71-0P 524961-31-7P 524961-33-9P 524961-36-2P 524961-39-5P **524961-41-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of **polymeric** thiol-linked **prodrugs**)

IT 50-44-2, 6-Mercaptopurine 1791-13-5, Aspartic acid di-tert-butyl ester hydrochloride 3303-84-2 5292-43-3, tert-Butyl bromoacetate 13726-67-5 14358-33-9, Aspartic acid dimethyl ester hydrochloride 24277-39-2 136586-99-7 204133-25-5 259802-47-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of **polymeric** thiol-linked **prodrugs**)

IT 608-09-3P 150109-41-4P 150109-43-6P 152293-46-4P 153354-68-8P 167082-77-1P 188636-64-8P 396134-22-8P 452369-72-1P **474083-07-3P 474083-09-5P** 524961-30-6P 524961-32-8P 524961-35-1P 524961-37-3P 524961-38-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of **polymeric** thiol-linked **prodrugs**)

IT **524961-40-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of **polymeric** thiol-linked **prodrugs**)

IT **524961-41-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of **polymeric** thiol-linked **prodrugs**)

RN 524961-41-9 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, monoether with hydroxyacetyl-L-aspartoylbis[L-aspartoylbis[L-aspartoylbis[.beta.-alanine]]] octakis[(1H-purin-6-ylthio)methyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 3-A





PAGE 3-B



IT **474083-07-3P 474083-09-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of **polymeric** thiol-linked **prodrugs**)
RN 474083-07-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, monoether with N-(hydroxyacetyl)-L-aspartoylbis[L-aspartic acid] tetramethyl ester (9CI) (CA INDEX NAME)



RN 474083-09-5 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, monoether with N-(hydroxyacetyl)-L-aspartoylbis[L-aspartic acid] (9CI) (CA INDEX NAME)



IT **524961-40-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological

study); PREP (Preparation); USES (Uses)
(prepn. of **polymeric** thiol-linked **prodrugs**)

RN 524961-40-8 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, monoether with hydroxyacetyl-L-aspartoylbis[L-aspartoylbis[.beta.-alanine]] tetrakis[(1H-purin-6-ylthio)methyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 3-A



L18 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:657977 HCAPLUS
DOCUMENT NUMBER: 137:206540
TITLE: Terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**
INVENTOR(S): Choe, Yun Hwang; Greenwald, Richard B.
PATENT ASSIGNEE(S): Enzon, Inc., USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066066	A1	20020829	WO 2002-US4780	20020219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002161052	A1	20021031	US 2002-78649	20020219

PRIORITY APPLN. INFO.: US 2001-272511P P 20010220
OTHER SOURCE(S): MARPAT 137:206540
GI

If mine is allowed becomes 102(e)



I

AB Terminally-branched polymeric prodrug platforms capable of high degrees of loading are disclosed. In preferred aspects of the invention, the prodrug platform releases multiple parent compds. after each branch holding the active agent undergoes a benzyl elimination reaction. E.g., I was prepd. and antitumor activity was tested in mice.

IC ICM A61K047-30
ICS A61K039-385; A61K038-54

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 33, 35

ST **prodrug polymer** link **conjugate**; antitumor **prodrug** PEG deriv

IT **Drug delivery** systems
(**prodrugs**; terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

IT Antitumor agents
(terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

IT Polyoxyalkylenes, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

IT 147-94-4, Ara-c 148-82-3, Melphalan 524-38-9, N-Hydroxyphthalimide 13726-67-5, N-tert-Butoxycarbonylaspartic acid 25322-68-3, Peg 452369-70-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

IT 1791-13-5P, Aspartic acid di tert-butyl ester hydrochloride 14358-33-9P, Aspartic acid dimethyl ester hydrochloride 88457-23-2P 167082-77-1P 187978-51-4P 188636-64-8P 229958-24-1P 229958-26-3P 229958-32-1P 261364-51-6P 452347-51-2P 452347-65-8P 452347-68-1P 452347-80-7P 452347-83-0P 452369-71-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

IT 452347-72-7 452347-75-0

RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

IT **452369-72-1P 452943-24-7P 452952-59-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

IT **452951-19-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

IT **452943-24-7P 452952-59-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

RN 452943-24-7 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, 1-monoether with N-(hydroxyacetyl)-L-aspartoylbis[L-alanine] bis[2-[3-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-1,1-dimethyl-3-oxopropyl]-3,5-dimethylphenyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 452952-59-9 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, 1-monoether with N-(hydroxyacetyl)-L-aspartoylbis[L-alanine] bis[2-[3-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-1,1-dimethyl-3-oxopropyl]-3,6-dimethylphenyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **452951-19-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)
RN 452951-19-8 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, ester with N-carboxy-L-aspartoylbis[L-aspartoylbis[.beta.-alanine]] 3,3',3'',3'''-tetrakis[2-[3-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-1,1-dimethyl-3-oxopropyl]-3,5-dimethylphenyl] ester (1:1) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 3-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:657915 HCAPLUS
DOCUMENT NUMBER: 137:206534
TITLE: Terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**
INVENTOR(S): Choe, Yun Hwang; Greenwald, Richard B.
PATENT ASSIGNEE(S): Enzon, Inc., USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002065988	A2	20020829	WO 2002-US4781	20020219
WO 2002065988	A3	20030410		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002183259	A1	20021205	US 2002-78730 20020219

PRIORITY APPLN. INFO.: US 2001-270009P P 20010220
OTHER SOURCE(S): MARPAT 137:206534

AB Terminally-branched polymeric prodrug platforms capable of high degrees of loading are disclosed. In preferred aspects of the invention, the prodrug platform releases multiple parent compds. after each branch holding the active agent undergoes a benzyl elimination reaction. Methods of prepg. the prodrugs and using the same in the treatment of mammals are also disclosed. For example, a polyethylene glycol-cytosine arabinoside (PEG-Ara-C) conjugate was prepd. The PEG-Ara-C conjugate demonstrated in tumor-bearing mice about equiv. antitumor activity with native Ara-C at only 20% of the active parent compd.'s dose. The IC50 for the PEG-Ara-C conjugate and the native Ara-C was 448 and 10 nM, resp., as detd. in vitro using the P388/0 (murine lymphoid neoplasm) cell line.

IC ICM A61K
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 35
ST **polymer conjugate** prepn **prodrug** antitumor; polyethylene glycol **conjugate** prepn **prodrug** antitumor
IT **Polymers**, biological studies
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**conjugates**; prepn. of terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)
IT Antitumor agents
(prepn. of terminally-branched **polymeric** linkers and **polymeric conjugates** as antitumor **prodrugs**)
IT Polyoxyalkylenes, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)
IT **Drug delivery** systems
(**prodrugs**; prepn. of terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)
IT 452369-72-1P **452369-80-1P** **452369-87-8P** 452369-91-4P 452369-98-1P
RL: AMX (Analytical matrix); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

Mine would be 102(a)

IT 147-94-4, Ara-C 148-82-3, Melphalan
RL: ANT (Analyte); RCT (Reactant); ANST (Analytical study); RACT (Reactant or reagent)
(prepn. of terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

IT 524-38-9, N-Hydroxyphthalimide 623-05-2, 4-Hydroxymethyl phenol 1791-13-5, Aspartic acid di-tert-butyl ester hydrochloride 4397-14-2, 4-Hydroxy-3,5-dimethylbenzyl alcohol 15761-38-3 25322-68-3 153086-78-3 261364-63-0 452369-70-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

IT 88457-23-2P 126070-20-0P 452347-51-2P 452369-71-0P 452369-73-2P 452369-74-3P 452369-75-4P 452369-76-5P 452369-77-6P 452369-79-8P 452369-81-2P 452369-82-3P 452369-83-4P 452369-84-5P 452369-86-7P 452369-88-9P 452369-90-3P 452369-92-5P 452369-93-6P 452369-94-7P 452369-95-8P 452369-97-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

IT 147-94-4DP, Ara-C, **polymer conjugates** 148-82-3DP, Melphalan, **polymer conjugates** 553-27-5DP, **polymer conjugates** 20830-81-3DP, Daunorubicin, **polymer conjugates** 23214-92-8DP, Doxorubicin, **polymer conjugates** 95058-81-4DP, Gemcitabine, **polymer conjugates** 111858-35-6DP, **polymer conjugates**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

IT **452369-80-1P 452369-87-8P**
RL: AMX (Analytical matrix); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of terminally-branched **polymeric** linkers and **polymeric conjugates** as **prodrugs**)

RN 452369-80-1 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, 1-monoether with N-(hydroxyacetyl)-L-aspartoylbis[L-alanine] bis[4-[[[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]carbonyl]oxy]methyl]-2,6-dimethylphenyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 452369-87-8 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[(4S)-17-[4-[[[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]carbonyl]oxy]methyl]phenoxy]-4-[12-[4-[[[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]carbonyl]oxy]methyl]phenoxy]-1,12-dioxo-5,8-dioxa-2,11-diazadodec-1-yl]-2,6,17-trioxo-10,13-dioxa-3,7,16-triazaheptadec-1-yl]-.omega.-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

L18 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:616193 HCAPLUS
DOCUMENT NUMBER: 137:174933
TITLE: Modulated-release **polymeric** silicate particles for aerosol delivery
INVENTOR(S): Zhu, Yaping; Stefanos, Simon; Adjei, Akwete L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002110528	A1	20020815	US 2001-784673	20010215
US 6544497	B2	20030408		
WO 2002066011	A1	20020829	WO 2002-US4286	20020213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-784673 A 20010215

AB A modulated release aerosol formulation comprises a polymer, e.g. silica gel or fumed silica gel, having a selected medicament assocd. there with, a fluid carrier for carrying and delivering the construct and a stabilizer. The polymer is present in an amt. of about 0.000001-10%. A

medicament comprises a protein or peptide with a mol. size of about 1-150 kD, such as insulin, amylin, an interleukin, an interferon, heparin, a thrombolytic, an antitrypsin, a hormone, a growth factor, an enzyme, etc. A stabilizer is selected from dipeptides and tripeptides. A method of treating in a human or an animal a condition capable of treatment by dermal, sublingual, buccal, oral, or nasal application comprises administering an aerosol formulation in a canister equipped with a metered dose valve.

IC ICM A61L009-04
ICS A61K009-14

NCL 424046000

CC 63-6 (Pharmaceuticals)

ST **polymer** silicate particle aerosol **slow** drug **release**; protein peptide aerosol **polymer** silicate particle; dipeptide tripeptide stabilizer **polymer** silicate particle

IT **Drug delivery** systems
(aerosols, inhalants; modulated-release **polymeric** silicate particles for aerosol delivery)

IT **Drug delivery** systems
(aerosols; modulated-release **polymeric** silicate particles for aerosol delivery)

IT **Drug delivery** systems
(buccal; modulated-release **polymeric** silicate particles for aerosol delivery)

IT **Drug delivery** systems
(carriers, fluid; modulated-release **polymeric** silicate particles for aerosol delivery)

IT Hydrocarbons, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorofluorocarbons, fluid carriers; modulated-release **polymeric** silicate particles for aerosol delivery)

IT Air
(compressed, fluid carrier; modulated-release **polymeric** silicate particles for aerosol delivery)

IT Hydrocarbons, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fluid carriers; modulated-release **polymeric** silicate particles for aerosol delivery)

IT Anti-infective agents
Antibiotics
Antidiabetic agents
Human
Propellants (sprays and foams)
Skin preparations (pharmaceutical)
Stabilizing agents
Thrombolytics
Vaccines
(modulated-release **polymeric** silicate particles for aerosol delivery)

IT Bentonite, biological studies
Bone morphogenetic proteins
Cytokines
Enzymes, biological studies
Growth factors, animal
Hemopoietins
Hormones, animal, biological studies
Immunoglobulins
Interferons
Interleukins

Kaolin, biological studies
Mica-group minerals, biological studies
Nucleic acids
Oligonucleotides
Pumice
Silanes
Silica gel, biological studies
Siloxanes (nonpolymeric)
Tumor necrosis factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulated-release **polymeric** silicate particles for aerosol delivery)

IT Peptides, biological studies
Proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulated-release **polymeric** silicate particles for aerosol delivery of protein and peptide drugs)

IT Lung
(modulated-release **polymeric** silicate particles for aerosol lung delivery)

IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; modulated-release **polymeric** silicate particles for aerosol delivery)

IT **Drug delivery** systems
(nasal; modulated-release **polymeric** silicate particles for aerosol delivery)

IT **Drug delivery** systems
(oral; modulated-release **polymeric** silicate particles for aerosol delivery)

IT **Drug delivery** systems
(particles; modulated-release **polymeric** silicate particles for aerosol delivery)

IT Silicates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(poly-; modulated-release **polymeric** silicate particles for aerosol delivery)

IT **Drug delivery** systems
(**slow-release**; modulated-**release** **polymeric** silicate particles for aerosol delivery)

IT Dipeptides
Tripeptides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilizers; modulated-release **polymeric** silicate particles for aerosol delivery)

IT 64-17-5, Ethanol, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cosolvent; modulated-release **polymeric** silicate particles for aerosol delivery)

IT 74-98-6, n-Propane, biological studies 106-97-8, n-Butane, biological studies 124-38-9, Carbon dioxide, biological studies 431-89-0, 1,1,1,2,3,3,3-Heptafluoropropane 811-97-2, 1,1,1,2-Tetrafluoroethane 7727-37-9, Nitrogen, biological studies 26760-64-5, Isopentene
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fluid carrier; modulated-release **polymeric** silicate particles for aerosol delivery)

IT 9001-92-7, Protease
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; modulated-release **polymeric** silicate particles for aerosol delivery)

IT 9004-10-8, Insulin, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulated-release **polymeric** silicate particles for aerosol delivery)

IT 50-60-2, Phentolamine 58-82-2, Bradykinin 64-77-7, Tolbutamide 75-69-4, Propellant 11 75-71-8 76-14-2, Propellant 114 94-20-2, Chlorpropamide 556-50-3, Glycylglycine 636-58-8, .gamma.-L-Glutamyl-L-cysteine 968-81-0, Acetohexamide 1050-28-8, L-Tyrosyl-L-tyrosine 1066-17-7, Colistin 1115-70-4, Glucophage 1156-19-0, Tolazamide 1318-93-0, Montmorillonite, biological studies 1343-98-2, Silicic acid 1344-28-1, Aluminum oxide, biological studies 1405-87-4, Bacitracin 1405-97-6, Gramicidin 1406-11-7, Polymyxin 3061-88-9, L-Alanyl-L-tyrosine **3106-85-2** 7412-78-4 7412-78-4D, **conjugates** 7631-86-9, Silicon dioxide, biological studies 7699-41-4, Metasilicic acid 8011-61-8, Tyrocidine 9002-64-6, Parathyroid hormone 9003-98-9, DNase 9004-10-8D, Insulin, analogs 9005-49-6, Heparin, biological studies 9007-12-9, Calcitonin 9007-92-5, Glucagon, biological studies 9015-94-5, Renin, biological studies 9025-39-2, Heparinase 9034-39-3, Growth hormone-releasing hormone 9034-40-6, LH-RH 9035-81-8, Antitrypsin 9061-61-4, Nerve growth factor 10193-36-9, Orthosilicic acid 10238-21-8, Glyburide 11096-26-7, Erythropoietin 12174-11-7, Attapulgite 13433-09-5, L-Aspartyl-L-phenylalanine 14807-96-6, Talc, biological studies 20638-18-0, Disilicic acid 24305-27-9, TRH 29094-61-9, Glipizide 31324-97-7 32461-59-9, N-Acetyl-L-cysteinyl-glycine 36791-04-5, Ribavirin 51110-01-1, Somatostatin 53678-77-6, Muramyl dipeptide 53714-56-0, Leuprolide 57956-13-5, Trisilicic acid 65807-02-5, Goserelin 70904-56-2, L-Tyrosyl-L-arginine 72636-02-3 72636-02-3D, **conjugates** 74863-12-0, L-Arginyl-L-tyrosine 76932-56-4, Nafarelin 79217-60-0, Cyclosporin 81627-83-0, Macrophage-colony stimulating factor 83150-76-9, Octreotide 85637-73-6, ANP 89750-14-1, Glucagon-like peptide I 106602-62-4, Amylin 124389-07-7, Muramyl tripeptide 143011-72-7, G-CSF 391929-04-7, Deltirex 391929-05-8, G-SF 446045-27-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulated-release **polymeric** silicate particles for aerosol delivery)

IT 19246-18-5, L-Cysteinylglycine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilizer; modulated-release **polymeric** silicate particles for aerosol delivery)

IT **3106-85-2**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulated-release **polymeric** silicate particles for aerosol delivery)

RN 3106-85-2 HCAPLUS
CN L-Glutamic acid, N-acetyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:385000 HCAPLUS
DOCUMENT NUMBER: 136:380138
TITLE: Compounds and methods for modulating junctional adhesion molecule-mediated functions
INVENTOR(S): Blaschuk, Orest W.; Symonds, James Matthew; Gour, Barbara J.
PATENT ASSIGNEE(S): Adherex Technologies, Inc., Can.
SOURCE: U.S., 26 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6391855	B1	20020521	US 1999-324541	19990602
US 2003027761	A1	20030206	US 2002-119537	20020408

PRIORITY APPLN. INFO.: US 1999-324541 A3 19990602

AB Methods are provided for using modulating agents to enhance or inhibit junctional adhesion mol. (JAM)-mediated cell adhesion in a variety of in vivo and in vitro contexts. The modulating agents comprise at least one JAM cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the JAM cell adhesion recognition sequence. Modulating agents may addnl. comprise one or more cell adhesion recognition sequences recognized by other adhesion mols. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

IC ICM A61K038-04
ICS A61K038-17; C07K007-04; C07K017-00
NCL 514017000
CC 1-12 (Pharmacology)
IT Adhesion, biological
Drug delivery systems
(compds. and methods for modulating junctional adhesion mol.-mediated functions)
IT Bioreactors
Membranes, nonbiological
Microparticles
Ultrathin films
(**conjugates** with cell adhesion-modulating agents; compds. and methods for modulating junctional adhesion mol.-mediated functions)
IT Drugs
(**conjugates**, and detectable marker **conjugates**, with cell adhesion-modulating agents; compds. and methods for modulating junctional adhesion mol.-mediated functions)
IT **Polymers**, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**conjugates**, with cell adhesion-modulating agents; compds. and methods for modulating junctional adhesion mol.-mediated functions)
IT Medical goods
(plastic dishes, **conjugates** with cell adhesion-modulating agents; compds. and methods for modulating junctional adhesion mol.-mediated functions)
IT Pipes and Tubes
(plastic tubes, **conjugates** with cell adhesion-modulating agents; compds. and methods for modulating junctional adhesion

mol.-mediated functions)

IT **Drug delivery** systems
(**sustained-release**; compds. and methods for modulating junctional adhesion mol.-mediated functions)

IT Medical goods
(sutures, **conjugates** with cell adhesion-modulating agents; compds. and methods for modulating junctional adhesion mol.-mediated functions)

IT **Drug delivery** systems
(targeting agent **conjugates** with cell adhesion-modulating agents; compds. and methods for modulating junctional adhesion mol.-mediated functions)

IT 73205-86-4 143304-79-4 175294-45-8 222169-83-7 **222169-86-0** 231282-25-0 231282-43-2 249636-29-1 250741-68-5 267423-25-6 427885-44-7 427885-45-8
RL: PRP (Properties)
(unclaimed sequence; compds. and methods for modulating junctional adhesion mol.-mediated functions)

IT **222169-86-0**
RL: PRP (Properties)
(unclaimed sequence; compds. and methods for modulating junctional adhesion mol.-mediated functions)

RN 222169-86-0 HCAPLUS

CN L-Valine, L-phenylalanyl-L-histidyl-L-leucyl-L-arginyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-.alpha.-aspartyl-L-isoleucyl-L-asparaginylglycyl-L-asparaginyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:107826 HCAPLUS
DOCUMENT NUMBER: 136:172758
TITLE: Terminally-branched **polymeric** linkers containing extension moieties for **prodrug conjugates**
INVENTOR(S): Greenwald, Richard B.; Choe, Yun H.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 32 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002015691	A1	20020207	US 2001-823296	20010329
PRIORITY APPLN. INFO.:			US 2000-193931P P	20000331

AB The present invention relates to polymer-based (e.g., PEG) conjugates having increased therapeutic **payloads**. In particular, the invention relates to the use of extension moieties which increase the efficiency of the loading of drugs onto the polymeric carriers. A variety of prodrugs were prepd. from ara-C and PEG derivs. by using spacer groups. The prodrug demonstrated better antitumor activity than ara-C alone. The prodrug produced complete tumor regression.

IC ICM A61K031-785
ICS C08G073-00
NCL 424078360
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 37
ST **polymer** linker **prodrug conjugate** prepn; araC
PEG linker **prodrug** antitumor prepn

marked earlier claims priority of same provisional 8/15/03 This is my application!!

IT **Drug delivery** systems
(**polymer**-bound; terminally-branched **polymeric** linkers contg. extension moieties for **prodrug conjugates**)
IT **Drug delivery** systems
(**prodrugs**; terminally-branched **polymeric** linkers contg. extension moieties for **prodrug conjugates**)
IT Antitumor agents
Molecular weight distribution
(terminally-branched **polymeric** linkers contg. extension moieties for **prodrug conjugates**)
IT **396133-96-3P 396133-97-4P** 396133-98-5P
396133-99-6P 396134-00-2P 396134-01-3P
396134-02-4P 396134-06-8P 396134-07-9P
396134-08-0P 396134-09-1P 396134-10-4P
396134-11-5P 396134-12-6P 396134-15-9P
396134-16-0P 396134-17-1P 396134-18-2P
396134-19-3P 396134-20-6P 396134-21-7P
397244-13-2P 397244-15-4P 397244-37-0P 397244-38-1P 397244-39-2P
397244-40-5P 397245-64-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(terminally-branched **polymeric** linkers contg. extension moieties for **prodrug conjugates**)
IT 56-84-8D, L-Aspartic acid, PEG deriv. 96-53-7, 2-Thiazolidinethione 105-36-2 147-94-4, Ara-C 524-38-9, N-Hydroxyphthalimide 929-06-6 7689-03-4, Camptothecin 9004-74-4 13139-15-6 13726-67-5 19172-47-5, Lawesson's reagent 32315-10-9, Triphosgene 74124-79-1, N,N'-Disuccinimidyl carbonate 136586-99-7 153086-78-3 187848-53-9 396134-05-7 396712-38-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(terminally-branched **polymeric** linkers contg. extension moieties for **prodrug conjugates**)
IT 80681-05-6P 96989-50-3P 108466-89-3P 139115-91-6P 167082-77-1P 188636-64-8P 259802-47-6P 261364-63-0P 341551-69-7P 379711-88-3P 379711-89-4P 396133-72-5P 396133-74-7P 396133-75-8P 396133-77-0P 396133-78-1P 396133-79-2P 396133-81-6P 396133-82-7P 396133-83-8P 396133-85-0P 396133-86-1P 396133-88-3P 396133-89-4P 396133-90-7P 396133-92-9P 396133-93-0P 396133-95-2P 396134-04-6P
396134-13-7P 396134-14-8P 396134-22-8P
396134-24-0P 396134-25-1P 396134-28-4P 396134-30-8P
396134-31-9P 397245-65-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(terminally-branched **polymeric** linkers contg. extension moieties for **prodrug conjugates**)
IT **367928-61-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(terminally-branched **polymeric** linkers contg. extension moieties for **prodrug conjugates**)
IT **396133-96-3P 396133-97-4P 396133-99-6P**
396134-00-2P 396134-01-3P 396134-02-4P
396134-06-8P 396134-07-9P 396134-08-0P
396134-09-1P 396134-10-4P 396134-11-5P
396134-12-6P 396134-15-9P 396134-16-0P
396134-17-1P 396134-18-2P 396134-19-3P
396134-20-6P 396134-21-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(terminally-branched **polymeric** linkers contg. extension moieties for **prodrug conjugates**)

RN 396133-96-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[(4S)-14-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-4-[[[2-[2-[[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]carbonyl]oxy]ethoxy]ethyl]amino]carbonyl]-2,6,14-trioxo-10,13-dioxa-3,7-diazatetradec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 396133-97-4 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[(4S)-15-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-4-[[[2-[2-[2-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-2-oxoethoxy]ethoxy]ethyl]amino]carbonyl]-2,6,15-trioxo-10,13-dioxa-3,7-diazapentadec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 396133-99-6 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[(4S)-14-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-4-[[[2-[2-[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]thioxomethoxy]ethoxy]ethyl]amino]carbonyl]-2,6-dioxo-14-thioxo-10,13-dioxa-3,7-diazatetradec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 396134-00-2 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[(4S)-15-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-4-[[[2-[2-[2-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-2-thioxoethoxy]ethoxy]ethyl]amino]carbonyl]-2,6-dioxo-15-thioxo-10,13-dioxa-3,7-diazapentadec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 396134-01-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[(4S)-17-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-piperidinyl)amino]-4-[12-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-1-oxo-12-thioxo-5,8-dioxa-2,11-diazadodec-1-yl]-2,6-dioxo-17-thioxo-10,13-dioxa-3,7,16-triazaheptadec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 396134-02-4 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[(4S)-14-[[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]oxy]-4-[[[2-[2-[[[[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]oxy]carbonyl]oxy]ethoxy]ethyl]amino]carbonyl]-2,6,14-trioxo-10,13-dioxa-3,7-diazatetradec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 396134-06-8 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[15-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-4,4-bis[3-[[2-[2-[[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]carbonyl]oxy]ethoxy]ethyl]amino]-3-oxopropyl]-2,7,15-trioxo-11,14-dioxa-3,8-diazapentadec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-B



RN 396134-07-9 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[16-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-4,4-bis[3-[[2-[2-[2-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-2-oxoethoxy]ethoxy]ethyl]amino]-3-oxopropyl]-2,7,16-trioxo-11,14-dioxa-3,8-diazahexadec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-B



RN 396134-08-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[18-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-4,4-bis[14-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-3,14-dioxo-7,10-dioxa-4,13-diazatetradec-1-yl]-2,7,18-trioxo-11,14-dioxa-3,8,17-triazaoctadec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-B



PAGE 3-B



RN 396134-09-1 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[15-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-4,4-bis[3-[[2-[2-[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]thioxomethoxy]ethoxy]ethyl]amino]-3-oxopropyl]-2,7-dioxo-15-thioxo-11,14-dioxa-3,8-diazapentadec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-B



RN 396134-10-4 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[16-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-4,4-bis[3-[[2-[2-[2-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-2-thioxoethoxy]ethoxy]ethyl]amino]-3-oxopropyl]-2,7-dioxo-16-thioxo-11,14-dioxa-3,8-diazahexadec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-B



RN 396134-11-5 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[18-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-4,4-bis[14-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-3-oxo-14-thioxo-7,10-dioxa-4,13-diazatetradec-1-yl]-2,7-dioxo-18-thioxo-11,14-dioxa-3,8-diazaoctadec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-B



PAGE 3-B



RN 396134-12-6 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[15-[[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]oxy]-4,4'-bis[3-[[2-[2-[[[[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]oxy]carbonyl]oxy]ethoxy]ethyl]amino]-3-oxopropyl]-2,7,15-trioxo-11,14-dioxa-3,8-diazapentadec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 396134-15-9 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1-ether with N-(hydroxyacetyl)-L-aspartoylbis[N1,N4-bis[2-[2-[[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]carbonyl]oxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



RN 396134-16-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1-ether with N-(hydroxyacetyl)-L-aspartoylbis[N1,N4-bis[2-[2-[2-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-2-oxoethoxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



PAGE 4-B



RN 396134-17-1 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1-ether with N-(hydroxyacetyl)-L-aspartoylbis[N1,N4-bis[2-[2-[2-[[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]carbonyl]amino]ethoxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



PAGE 4-B



RN 396134-18-2 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1-ether with N-(hydroxyacetyl)-L-aspartoylbis[N1,N4-bis[2-[2-[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]thioxomethoxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



RN 396134-19-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1-ether with N-(hydroxyacetyl)-L-aspartoylbis[N1,N4-bis[2-[2-[2-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-2-thioxoethoxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



PAGE 4-B



RN 396134-20-6 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1-ether with N-(hydroxyacetyl)-L-aspartoylbis[N1,N4-bis[2-[2-[2-[[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]thioxomethyl]amino]ethoxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



PAGE 4-B



RN 396134-21-7 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, ether with hydroxyacetyl-L-aspartoylbis[N1,N4-bis[2-[2-[[[[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]oxy]carbonyl]oxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 3-A



IT **396134-13-7P 396134-14-8P 396134-24-0P**
396134-25-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(terminally-branched **polymeric** linkers contg. extension moieties for **prodrug conjugates**)
RN 396134-13-7 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, ether with N-(hydroxyacetyl)-L-aspartoylbis[L-aspartic acid] tetramethyl ester (9CI) (CA INDEX NAME)



RN 396134-14-8 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, ether with N-(hydroxyacetyl)-L-aspartoylbis[L-aspartic acid] (9CI) (CA INDEX NAME)



RN 396134-24-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, ether with N-(hydroxyacetyl)-L-aspartoylbis[L-aspartoylbis[L-aspartic acid]] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 396134-25-1 HCAPLUS
CN L-Aspartamide, N-[(1,1-dimethylethoxy)carbonyl]-L-aspartoylbis[N1,N4-bis[2-[2-[[[[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]oxy]carbonyl]oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



IT **367928-61-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(terminally-branched **polymeric** linkers contg. extension moieties for **prodrug conjugates**)
RN 367928-61-8 HCAPLUS
CN L-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-L-aspartoylbis[L-aspartoylbis-, octamethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:72705 HCAPLUS
DOCUMENT NUMBER: 136:123688
TITLE: Preparation of biodegradable high molecular weight **polymeric** linkers and their drug **conjugates**
INVENTOR(S): Greenwald, Richard B.; Zhao, Hong
PATENT ASSIGNEE(S): Greenwald, Richard, USA
SOURCE: U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. 6,251,382.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002009426	A1	20020124	US 2001-888072	20010622
US 6251382	B1	20010626	US 1999-293557	19990415

PRIORITY APPLN. INFO.: US 1998-82105P P 19980417
US 1999-293557 A2 19990415
OTHER SOURCE(S): MARPAT 136:123688

AB The present invention includes polymeric transport systems such as prodrugs of polyoxyethylene with pharmaceuticals such as daunorubicin, and camptothecin. A soln. of of m-PEG acid, diaminopimelic aspartic acid camptothecin TFA salt, a 50% soln. of 1-propanephosphonic acid cyclic anhydride in EtOAc and N-dimethylaminopyridine in dry dichloromethane was stirred at room temp. overnight followed by washing with 1% aq. NaHCO3 and 0.1N HCl soln. The solvent was removed , and the residue was crystd. from 2-propanol to yield the product.

IC ICM A61K031-785
ICS C08G063-91
NCL 424078180
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 26, 34, 37
ST **polymer prodrug conjugate** prepn; anticancer
polymer prodrug prepn; polyoxyethylene **prodrug** anticancer prepn
IT Antitumor agents
(prepn. of biodegradable high mol. wt. **polymeric** linkers and their drug **conjugates**)
IT **Drug delivery** systems
(**prodrugs**; prepn. of biodegradable high mol. wt. **polymeric** linkers and their drug **conjugates**)
IT 96-53-7, 2-Thiazolidinethione 583-93-7 1791-13-5 6057-90-5 7689-03-4 13726-67-5 23541-50-6 24424-99-5 67665-18-3 204133-37-9 391612-43-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of biodegradable high mol. wt. **polymeric** linkers and their drug **conjugates**)
IT 98469-29-5P 247920-06-5P 345967-44-4P 345967-45-5P 345967-47-7P 345967-49-9P 345967-51-3P 391612-44-5P 391612-45-6P 391612-46-7P 391612-47-8P 391612-48-9P 391612-49-0P 391669-40-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of biodegradable high mol. wt. **polymeric** linkers and their drug **conjugates**)
IT **391612-50-3P** 391612-51-4P **391612-52-5P** 391669-39-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of biodegradable high mol. wt. **polymeric** linkers and their drug **conjugates**)
IT 147-94-4D, Cytosine arabinoside, **prodrugs** 148-82-3D, Melphalan, **prodrugs** 2067-58-5D, **prodrugs** 20830-81-3D, **prodrugs** 23214-92-8D, Doxorubicin, **prodrugs** 95058-81-4D, Gemcitabine, **prodrugs**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of biodegradable high mol. wt. **polymeric** linkers and their drug **conjugates**)
IT **391612-50-3P 391612-52-5P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of biodegradable high mol. wt. **polymeric** linkers and their drug **conjugates**)

RN 391612-50-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-methoxy-, ether with N-[[2-[(hydroxyacetyl)amino]-1-[[(hydroxyacetyl)amino]methyl]ethoxy]carbonyl]-.beta.-alanyl-L-aspartoyl-L-alanine bis[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (2:1) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 391612-52-5 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-methoxy-, ether with 3',3'''-[N-[[2-[(hydroxyacetyl)amino]-1-[[(hydroxyacetyl)amino]methyl]etho

xy]carbonyl]-.beta.-alanyl-L-aspartoyldiimino]bis[(8S,10S)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[(2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-5,12-naphthacenedione] (2:1) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L18 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:934014 HCAPLUS
DOCUMENT NUMBER: 136:48463
TITLE: Cyclic peptide compounds and method for modulating neurite outgrowth
INVENTOR(S): Blaschuk, Orest W.; Gour, Barbara J.
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: U.S., 62 pp., Cont.-in-part of U.S. Ser. No. 115,395.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6333307	B1	20011225	US 1999-250059	19990212
US 6031072	A	20000229	US 1997-893534	19970711
US 6169071	B1	20010102	US 1997-996679	19971223
US 6207639	B1	20010327	US 1998-115395	19980714
US 2002151475	A1	20021017	US 2001-6982	20011204

PRIORITY APPLN. INFO.: US 1996-21612P P 19960712
US 1997-893534 A2 19970711
US 1997-996679 A2 19971223
US 1998-115395 A2 19980714
US 2000-507102 A1 20000217
OTHER SOURCE(S): MARPAT 136:48463

AB Modulating agents comprising cyclic peptides, and compns. comprising such modulating agents, are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compns. for modulating and/or directing neurite outgrowth in a variety of contexts are also provided.

IC ICM A61K038-12
ICS A61K038-00
NCL 514009000
CC 1-11 (Pharmacology)
IT Drugs
(and drug-cyclic peptide **conjugates**; cyclic peptide compds. and method for modulating neurite outgrowth)
IT Adhesion, biological
Bioreactors
Drug delivery systems
Immobilization, molecular
Microparticles
Nervous system agents
Structure-activity relationship
(cyclic peptide compds. and method for modulating neurite outgrowth)
IT Plastics, biological studies
Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic peptide compds. and method for modulating neurite outgrowth)
IT **Drug delivery** systems
(implants; cyclic peptide compds. and method for modulating neurite outgrowth)
IT **Drug delivery** systems
(**sustained-release**; cyclic peptide compds. and method for modulating neurite outgrowth)
IT **Drug delivery** systems
(targeting agent-cyclic peptide **conjugates**; cyclic peptide compds. and method for modulating neurite outgrowth)
IT 73205-86-4 110590-64-2 143304-79-4 170032-25-4 175294-44-7

202527-94-4 202527-98-8 202528-00-5 202528-03-8 202528-07-2
202528-10-7 214684-50-1 214684-52-3 **222169-86-0**
222169-89-3 222169-90-6 229971-74-8 229971-80-6 249636-29-1
250268-78-1 250268-79-2 250268-80-5 250268-81-6 250268-82-7
250268-83-8 250268-84-9 250268-85-0 250268-86-1 250268-87-2
250268-88-3 250268-89-4 250268-90-7 250268-91-8 250271-33-1
250271-34-2 250271-35-3 250271-36-4 250271-37-5 250271-39-7
250271-41-1 255369-45-0 289914-94-9 **317320-19-7**
331474-64-7 331474-65-8 331474-66-9 331474-67-0 331474-68-1
331474-69-2 331474-70-5 331474-71-6 331474-72-7 331474-73-8
331474-74-9 331474-75-0 331474-76-1 331474-77-2 331474-78-3
331474-79-4 331474-80-7 331474-81-8 331474-82-9 331474-83-0
331474-84-1 351974-94-2 351974-95-3 351974-96-4 351974-97-5
382656-70-4 382656-72-6 382656-73-7
RL: PRP (Properties)
(Unclaimed; cyclic peptide compds. and method for modulating neurite outgrowth)

IT **222169-86-0 317320-19-7**
RL: PRP (Properties)
(Unclaimed; cyclic peptide compds. and method for modulating neurite outgrowth)

RN 222169-86-0 HCAPLUS

CN L-Valine, L-phenylalanyl-L-histidyl-L-leucyl-L-arginyl-L-alanyl-L-histidyl-L-alanyl-L-valyl-L-.alpha.-aspartyl-L-isoleucyl-L-asparaginylglycyl-L-asparaginyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317320-19-7 HCAPLUS
CN Glycine, L-cysteinylglycyl-L-asparaginyl-L-leucyl-L-seryl-L-threonyl-L-cysteinyl-L-methionyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:886568 HCAPLUS
DOCUMENT NUMBER: 136:42803
TITLE: **Conjugate** addition reactions for the controlled delivery of pharmaceutically active compounds
INVENTOR(S): Hubbel, Jeffrey A.; Elbert, Donald; Schoenmakers, Ronald
PATENT ASSIGNEE(S): Eidgenossische Technische Hochschule Zurich, Switz.; Universitat Zurich
SOURCE: PCT Int. Appl., 221 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001092584	A1	20011206	WO 2001-US18101	20010604
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1292709	A1	20030319	EP 2001-941913	20010604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-586937 A2 20000602 ← after. priority date
WO 2001-US18101 W 20010604

OTHER SOURCE(S): MARPAT 136:42803

AB The invention features polymeric biomaterials formed by nucleophilic addn. reactions to conjugated unsatd. groups. These biomaterials may be used for medical treatments.

IC ICM C12Q001-68
ICS C07H021-04
CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 2, 34, 35
ST **polymer** biomaterial addn reaction **drug delivery**
IT Cations
(-binding agents; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)
IT Carbohydrates, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(-binding agents; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)
IT **Drug delivery** systems
(colloids; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)
IT Biological materials
Bone formation
Crosslinking agents
Drug delivery systems
Encapsulation
Human
Immobilization, molecular
Prosthetic materials and Prosthetics
Protein degradation
Substitution reaction, nucleophilic
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)
IT Myoglobins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)
IT Amides, biological studies
Esters, biological studies
Polyoxyalkylenes, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)
IT Nucleic acids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)
IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)
IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)
IT Ligands
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)
IT Addition reaction
(**conjugate**; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)
IT **Drug delivery** systems
(**controlled-release**; **conjugate** addn.

reactions for the **controlled** delivery of pharmaceutically active compds.)

IT **Drug delivery** systems
(gels; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(heparin-binding; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT **Drug delivery** systems
(hydrogels; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT **Polymerization**
(photopolymn.; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT **Drug delivery** systems
(**prodrugs**; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT Skin
(regeneration; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT **Polymers**, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-sol.; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT **Polymers**, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-swellable; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 9005-49-6, Heparin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(-binding agents; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT 380504-60-9P
RL: PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT 98-80-6, Phenylboronic acid 9061-61-4, Nerve growth factor 12619-70-4, Cyclodextrin
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT 26570-48-9P, Polyethylene glycol diacrylate 101661-95-4P 119388-27-1P 287184-65-0P 287184-66-1P 287184-69-4P
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT 9002-89-5, Polyvinyl alcohol 9003-01-4, Polyacrylic acid 9003-39-8, POLYVINYLPYRROLIDONE 25067-34-9 25189-55-3, Poly(N-isopropylacrylamide) 25322-68-3, Polyethylene glycol 25805-17-8, Poly(ethyloxazoline) 26793-34-0, Poly(dimethylacrylamide) 106392-12-5, Poly(ethylene oxide)-poly(propylene oxide) block copolymer 129128-87-6
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological

study); USES (Uses)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT 362-07-2, 2-Methoxyestradiol 23214-92-8, Doxorubicin 33069-62-4, Paclitaxel
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT 50-28-2, Estradiol, biological studies 50-91-9, 5-Fluorodeoxyuridine 7689-03-4, Camptothecin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.).

IT 287184-73-0P 287184-74-1P 287184-75-2P **287184-76-3P** **287184-77-4P** **287184-78-5P** **287184-79-6P** 287184-80-9P 287184-81-0P 287184-82-1P 287184-83-2P
RL: PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT **377733-59-0P**
RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT 76-84-6, Triphenylmethanol 107-96-0, 3-Mercaptopropionic acid 998-40-3, Tributylphosphine 2906-60-7 87199-17-5, 4-Formylphenylboronic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT 1095-85-8P, 2-Tritylthioethylamine 23214-92-8DP, Doxorubicin, thiopropionate derivs. 27144-18-9P, 3-Tritylthio-propionic acid 138441-75-5P 377733-50-1P 377733-53-4P 377733-56-7P 377733-62-5P 377733-64-7P 377733-66-9P 377733-67-0P 377733-69-2P 377733-71-6P 377733-74-9P 377733-75-0P 377733-76-1P 377733-77-2P 377733-78-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT 33069-62-4DP, Paclitaxel, polyethylene glycol **conjugates**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT 287413-07-4P
RL: PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT 9001-90-5, Plasmin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peptide; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT 380606-23-5 380606-24-6 380606-25-7 380606-26-8 380606-34-8
RL: PRP (Properties)
(unclaimed protein sequence; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT **380428-31-9** 380428-32-0 **380428-33-1**
RL: PRP (Properties)
(unclaimed sequence; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

IT **287184-76-3P 287184-77-4P 287184-78-5P 287184-79-6P**
RL: PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)

RN 287184-76-3 HCAPLUS
CN Glycine, glycyl-L-cysteinylglycyl-L-tyrosylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-seryl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 287184-77-4 HCAPLUS
CN L-Prolinamide, N-acetylglycyl-L-cysteinylglycyl-L-tyrosylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 287184-78-5 HCAPLUS
CN Glycine, glycyl-L-.alpha.-aspartylglycyl-L-serylglycyl-L-tyrosylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-seryl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 287184-79-6 HCAPLUS
CN L-Serine, glycyl-L-cysteinylglycyl-L-tyrosylglycyl-L-arginylglycyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **377733-59-0P**
RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(**conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)
RN 377733-59-0 HCAPLUS
CN L-Cysteinamide, N-acetylglycyl-L-cysteinylglycyl-L-tyrosylglycyl-L-arginylglycyl-L-asparaginyl-L-glutaminyl-S-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH_2

IT **380428-31-9 380428-33-1**
RL: PRP (Properties)
(unclaimed sequence; **conjugate** addn. reactions for the controlled delivery of pharmaceutically active compds.)
RN 380428-31-9 HCAPLUS
CN Glycine, glycyl-L-cysteinyl-L-asparaginyl-L-asparaginyl-L-arginylglycyl-L-.alpha.-aspartyl-L-asparaginyl-L-asparaginyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 380428-33-1 HCAPLUS
CN L-Proline, glycyl-L-cysteinylglycyl-L-tyrosylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:868181 HCAPLUS
DOCUMENT NUMBER: 136:11133
TITLE: Prolonged-release microspheres for injection and preparation method
INVENTOR(S): Dulieu, Claire; Richard, Joeel; Benoit, Jean-Pierre
PATENT ASSIGNEE(S): Mainelab, Fr.; Laboratoires des Produits Ethiques Ethypharm
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001089481	A1	20011129	WO 2001-FR1575	20010522
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2809309	A1	20011130	FR 2000-6587	20000523
BR 2001011054	A	20030415	BR 2001-11054	20010522
EP 1303259	A1	20030423	EP 2001-938300	20010522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 2002005552	A	20030120	NO 2002-5552	20021119

PRIORITY APPLN. INFO.: FR 2000-6587 A 20000523 ← post-date
WO 2001-FR1575 W 20010522

AB The invention concerns microspheres for injection comprising a protein active principle and an agent coating the active principle, designed to prolong its release, free of any trace of org. solvent, and obtainable by a coating method which involves contacting under agitation the active principle with the coating agent in a supercrit. fluid, said coating agent

being sol. in the supercrit. fluid. The protein active principle is not denatured. Microspheres of Gelucire 50/02 contg. bovine serum albumin was prepd. using carbon dioxide as supercrit. fluid.

IC ICM A61K009-16

CC 63-6 (Pharmaceuticals)

IT **Polymers**, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biodegradable; prolonged-release microspheres for injection and prepn. method)

IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**conjugates** with adenosine deaminase or L-asparaginase; prolonged-release microspheres for injection and prepn. method)

IT **Drug delivery** systems
(microspheres, **sustained-release**; prolonged-**release** microspheres for injection and prepn. method)

IT 57-10-3D, Palmitic acid, glycerides 57-11-4D, Stearic acid, glycerides 113-79-1, Arginine vasopressin 124-06-1, Ethyl myristate 544-63-8D, Myristic acid, glycerides 555-43-1, Dynasan 118 555-44-2, Dynasan 116 555-45-3, Dynasan 114 628-97-7, Ethyl palmitate 1407-47-2, Angiotensin 2462-63-7, Dioleoylphosphatidylethanolamine 2644-64-6, Dipalmitoylphosphatidylcholine 8001-27-2, Hirudin 9001-27-8 9001-28-9, Blood Coagulation factor IX 9002-64-6, Parathyroid hormone 9002-72-6, Somatotropin 9003-11-6, Ethylene oxide propylene oxide copolymer 9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin 9015-68-3D, L-Asparaginase, **conjugates** with PEG 9015-71-8, Corticotropin releasing hormone 9026-93-1D, Adenosine deaminase, **conjugates** with PEG 9033-10-7, Glycosylceramidase 9034-39-3, Growth hormone releasing factor 9034-40-6, Lhrh 9061-61-4, Nerve growth factor 24305-27-9, Thyrotropin releasing hormone 24980-41-4, Poly(.epsilon.-caprolactone 25248-42-4, Poly[oxy(1-oxo-1,6-hexanediyl)] 25322-68-3, Polyethylene glycol 25322-68-3D, PEG, **conjugates** with adenosine deaminase or L-asparaginase 26009-03-0, Polyglycolide 26063-00-3, Poly(.beta.-hydroxybutyrate 26161-42-2 26202-08-4, Polyglycolide 26780-50-7, Polylactide-co-glycolide **31362-50-2**, Bombesin 33135-50-1, Poly L-lactide 34346-01-5, Glycolic acid lactic acid copolymer 37221-79-7, Vasoactive intestinal peptide 51110-01-1, Somatostatin 57773-63-4, Triptorelin 61361-72-6, Dimyristoyl phosphatidylglycerol 65312-43-8, Blood coagulation factor VIIa 68737-67-7 78644-42-5, Polymalic acid 80043-53-4, Gastrin releasing peptide 83826-43-1, Octyldodecyl myristate 83869-56-1, Granulocyte macrophage colony stimulating factor 102190-94-3, Poly(hydroxyvaleric acid) 103370-86-1, Humoral hypercalcemic factor 105913-11-9, Plasminogen activator 106602-62-4, Amylin 117563-96-9, Polyethylene glycol-lactic acid block copolymer 120081-14-3D, derivs. 121181-53-1, Filgrastim 123774-72-1, Sargramostim 125622-72-2, Gelucire 50/02 133197-54-3 135968-09-1, Lenograstim 137061-48-4, Pituitary adenylate cyclase activating polypeptide 143011-72-7, Granulocyte colony stimulating factor
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prolonged-release microspheres for injection and prepn. method)

IT **31362-50-2**, Bombesin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prolonged-release microspheres for injection and prepn. method)

RN 31362-50-2 HCAPLUS

CN Bombesin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B







REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:535199 HCAPLUS
DOCUMENT NUMBER: 133:155432
TITLE: Preparation of biomaterials formed by nucleophilic addition reaction to **conjugated** unsaturated **polymers**
INVENTOR(S): Hubbell, Jeffrey A.; Elbert, Donald; Lutolf, Matthias; Pratt, Alison; Schoenmakers, Ronald; Tirelli, Nicola; Vernon, Brent
PATENT ASSIGNEE(S): Switz.
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044808	A1	20000803	WO 2000-US2608	20000201
W: AU, BR, CA, CN, CZ, GE, HU, ID, IL, IS, JP, KR, MX, NO, NZ, PL, RO, RU, SG, TR, UA, US, YU				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2359318	AA	20000803	CA 2000-2359318	20000201
EP 1181323	A1	20020227	EP 2000-910049	20000201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002535108	T2	20021022	JP 2000-596061	20000201

PRIORITY APPLN. INFO.: US 1999-118093P A2 19990201
WO 2000-US2608 W 20000201

102(a)

AB The invention features polymeric biomaterials formed by nucleophilic addn. reactions to conjugated unsatd. groups. These biomaterials may be used for medical treatments. Thus, polyethylene glycol triacrylate was dissolved in pH 8 50-mM HEPES buffered saline at 20% with 2% albumin. PEG dithiol was dissolved in pH 5.6 1-mM MES buffered saline at 20%. The liq. soln. was added to cyclohexane contg. Hypermer B239. The polymd., protein-contg. spheres were then washed with cyclohexane to remove surfactant, followed by drying in vacuum to remove cyclohexane. The particles were then resuspended in pH 7.4 HEPES buffered saline. Protein concns. in the resuspending medium were detd. from a concn. std. curve for albumin at 280 nm.

IC ICM C08G063-48
ICS C08G063-91; C12N011-02; C12N011-04; C12N011-06; C12N011-08; G01N033-544; G01N033-545; G01N033-546; G01N033-549
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 34, 37
ST biomaterial nucleophilic addn reaction unsatd **polymer**; PEG acrylate cysteine addn reaction biomaterial; **drug delivery** nucleophilic addn reaction unsatd **polymer**; implant nucleophilic addn reaction unsatd **polymer**
IT Skin
(artificial; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)
IT **Drug delivery** systems
(**controlled-release**; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)
IT Meninges
(dura mater; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)
IT Bone formation
(ectopic; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)
IT **Drug delivery** systems
(gels; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)
IT Prosthetic materials and Prosthetics
(implants; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)
IT Addition reaction
Addition reaction kinetics
(nucleophilic; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)
IT Plasmid vectors
(pUC18; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)
IT Biocompatibility
Blood vessel
Cartilage
Emulsifying agents
Encapsulation
Gelation
Hydrophile-lipophile balance value
Immobilization, biochemical
Intestine
Lung
Medical goods
Molecular cloning
Molecular weight distribution
Nerve
Protein sequences
Strength
Surfactants
Swelling, physical
Viscosity
Young's modulus
cDNA sequences
(prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)
IT Fusion proteins (chimeric proteins)
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic

use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT Antisense DNA
DNA
Growth factors, animal
Nucleic acids
RNA
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT Polyoxyalkylenes, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT Myoglobins
Peptides, biological studies
Polyoxyalkylenes, biological studies
Proteins, general, biological studies
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT **Drug delivery** systems
(**prodrugs**; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT 287413-06-3P
RL: BPN (Biosynthetic preparation); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(amino acid sequence; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT 287413-07-4P
RL: BPN (Biosynthetic preparation); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(nucleotide sequence; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT 9061-61-4, Nerve growth factor
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(plasmid encoding; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT 287184-83-2
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT 7575-23-7DP, **conjugate** addn. product with PEG diacrylate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT 52-90-4, Cysteine, reactions 100-43-6, 4-Vinylpyridine 102-56-7, 2,5-Dimethoxyaniline 105-36-2, Ethyl 2-bromoacetate 3350-78-5 7575-23-7 10487-71-5, Crotonoyl chloride 25322-68-3 31694-55-0 33007-83-9 287184-70-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of biomaterials formed by nucleophilic addn. reaction to

conjugated unsatd. **polymers**)

IT 26570-48-9DP, **conjugate** addn. product with trimethylolpropane tris(3-mercaptopropionate) or pentaerythritol tetrakis(3-mercaptopropionate) 26570-48-9P 33007-83-9DP, **conjugate** addn. product with PEG diacrylate 39927-08-7P 101661-95-4P 119388-27-1P, Lactide-polyethylene glycol block copolymer 287184-65-0P 287184-66-1P 287184-67-2P 287184-68-3P 287184-69-4P 287184-72-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT 9002-89-5, Poly(vinyl alcohol) 9003-01-4, Poly(acrylic acid) 9003-05-8, Polyacrylamide 9003-11-6 9003-39-8, PVP 9010-77-9, Acrylic acid-ethylene copolymer 25067-33-8, Ethylene-N-vinylpyrrolidone copolymer 25067-34-9, Ethylene-vinyl alcohol copolymer 25085-79-4, Ethylene-maleic acid copolymer 25805-17-8, Poly(ethyloxazoline) 26099-09-2, Polymaleic acid 287184-73-0 287184-74-1 287184-75-2 **287184-76-3 287184-77-4 287184-78-5 287184-79-6** 287184-80-9 287184-81-0 287184-82-1
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT 31694-55-0DP, **conjugate** addn. product with cysteine(thiol contg.) contg. peptide 287184-73-0DP, **conjugate** addn. product with ethoxylated glycerol triacrylate
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT 287480-20-0 287480-26-6
RL: PRP (Properties)
(unclaimed protein sequence; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT **91037-65-9 93674-99-8 93675-01-5** 107978-83-6 109053-05-6 109053-13-6 110590-64-2 111771-60-9 122192-97-6 124575-92-4 131167-89-0 134580-64-6 134652-20-3 134652-24-7 134652-25-8 134652-26-9 134652-35-0 210159-04-9 **214343-81-4** 214343-83-6 287393-81-1 287393-82-2 287393-83-3
RL: PRP (Properties)
(unclaimed sequence; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

IT **287184-76-3 287184-77-4 287184-78-5 287184-79-6**
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

RN 287184-76-3 HCAPLUS
CN Glycine, glycyl-L-cysteinylglycyl-L-tyrosylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-seryl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 287184-77-4 HCAPLUS
CN L-Prolinamide, N-acetylglycyl-L-cysteinylglycyl-L-tyrosylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 287184-78-5 HCAPLUS
CN Glycine, glycyl-L-.alpha.-aspartylglycyl-L-serylglycyl-L-tyrosylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-seryl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 287184-79-6 HCAPLUS
CN L-Serine, glycyl-L-cysteinylglycyl-L-tyrosylglycyl-L-arginylglycyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **91037-65-9 93674-99-8 93675-01-5**
214343-81-4
RL: PRP (Properties)
(unclaimed sequence; prepn. of biomaterials formed by nucleophilic addn. reaction to **conjugated** unsatd. **polymers**)

RN 91037-65-9 HCAPLUS
CN L-Serine, L-arginylglycyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 93674-99-8 HCAPLUS
CN L-Valine, L-arginylglycyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 93675-01-5 HCAPLUS
CN L-Threonine, L-arginylglycyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 214343-81-4 HCAPLUS
CN L-Asparagine, L-leucyl-L-arginylglycyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:465028 HCAPLUS
DOCUMENT NUMBER: 127:79784
TITLE: Diagnosis or therapy of epithelial carcinoma based on CD44 gene variant exon v6 and encoded antigen fragment using antibodies
INVENTOR(S): Heider, Karl-Heinz; Adolf, Guenther; Ostermann, Elinborg; Patzelt, Erik; Sproll, Marlies
PATENT ASSIGNEE(S): Boehringer Ingelheim International Gmbh, Germany
SOURCE: Ger. Offen., 13 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19545472	A1	19970612	DE 1995-19545472	19951206
ZA 9610183	A	19970606	ZA 1996-10183	19961204
CA 2239709	AA	19970612	CA 1996-2239709	19961205
WO 9721104	A1	19970612	WO 1996-EP5448	19961205

W: AU, BG, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, TR, UA, US, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

AU 9711773	A1	19970627	AU 1997-11773	19961205	
AU 726704	B2	20001116			
EP 865609	A1	19980923	EP 1996-942362	19961205	
EP 865609	B1	20030319			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI					
CN 1207811	A	19990210	CN 1996-199248	19961205	
BR 9611901	A	19990302	BR 1996-11901	19961205	
JP 2000502067	T2	20000222	JP 1997-520993	19961205	
NZ 324314	A	20000228	NZ 1996-324314	19961205	
EE 3783	B1	20020617	EE 1998-164	19961205	
RU 2193779	C2	20021127	RU 1998-112600	19961205	
PL 184521	B1	20021129	PL 1996-327066	19961205	
AT 235056	E	20030415	AT 1996-942362	19961205	
NO 9802588	A	19980805	NO 1998-2588	19980605	
BG 62985	B1	20001229	BG 1998-102513	19980605	
PRIORITY APPLN. INFO.:			DE 1995-19545472 A	19951206	
			DE 1996-19615074 A	19960417	
			WO 1996-EP5448 W	19961205	

AB A method for diagnosis and therapy of epithelial carcinomas is disclosed that is based on the CD44 antigen fragment expressed by the gene variable exon v6. Immunol. detn. of the variant antigen fragment using antibody probes is included. Esp. useful is the monoclonal antibody BIWA-1 (VFF-18). Immunotherapy using antibodies is also claimed.

IC ICM C12Q001-68
ICS G01N033-574; A61K039-395

CC 14-1 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 1, 15

IT Fluorescent probes
(**conjugates**, with antibody; diagnosis or therapy of epithelial carcinoma based on CD44 gene variant exon v6 and encoded antigen fragment using antibodies)

IT Antitumor agents
Cytokines
Enzymes, biological studies
Immunomodulators
Toxins
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(**conjugates**, with antibody; diagnosis or therapy of epithelial carcinoma based on CD44 gene variant exon v6 and encoded antigen fragment using antibodies)

IT Carcinoma
Epitopes
Immunotherapy
PCR (**polymerase** chain reaction)
(diagnosis or therapy of epithelial carcinoma based on CD44 gene variant exon v6 and encoded antigen fragment using antibodies)

IT **Drug delivery** systems
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(**prodrugs**, **conjugates**, with antibody; diagnosis or therapy of epithelial carcinoma based on CD44 gene variant exon v6 and encoded antigen fragment using antibodies)

IT **161123-11-1**
RL: ANT (Analyte); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CD44 antigen exon 6-encoded sequence epitope-contg. fragment; diagnosis or therapy of epithelial carcinoma based on CD44 gene variant exon v6 and encoded antigen fragment using antibodies)

IT **161123-11-1**
RL: ANT (Analyte); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(CD44 antigen exon 6-encoded sequence epitope-contg. fragment; diagnosis or therapy of epithelial carcinoma based on CD44 gene variant exon v6 and encoded antigen fragment using antibodies)
RN 161123-11-1 HCAPLUS
CN L-Threonine, L-glutaminyl-L-tryptophyl-L-phenylalanylglycyl-L-asparaginyl-L-arginyl-L-tryptophyl-L-histidyl-L-.alpha.-glutamylglycyl-L-tyrosyl-L-arginyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B